Options Recaps, Fresh Ideas

Options Reviews

We issued a couple of fresh options ideas in yesterday morning’s report, concerning SMAR and SFIX, which had both reported quarterly earnings in the premarket. We took interest in the SMAR 12/18 $70-75 Calls and the SFIX Weekly $45-50 Calls. 

We witnessed good intraday performances in both cases, with SMAR outperforming SFIX, but not by a whole lot. Both plays will have provided our readers with plenty of opportunity to get in and out for some nice gains on the day.

Here were the total ranges and possible profits on those contracts: 

SMAR 12/18 $70-75 Calls
$70
: 2.10-6.80 (+136%)
$75: 1.11-3.65 (+219%)
_____

SFIX Weekly $45-50 Calls 
$45: 5.00-7.99 (+136%)
$46: 4.46-7.29 (+219%)
$50: 1.90-4.59 (+222%)


Fresh Options Ideas:

GME Weekly $15.50-14 Puts
ZI 04/16 $45-50 Calls
SPLK Weekly $160 Calls
ROKU Weekly $310-315 Calls 


Extended Watchlist:
CURR, SFOR, NECA, APYP, TLSS, BSSP

Blue Horseshoe Stocks: APYP Recap & More

AppYea, Inc. APYP

We re-alerted our readers on APYP on Friday morning, after having included it in our premarket report exactly two weeks ago today. It has made some good progress since then, so we’d like to kick things off this morning by providing an update on the moves it has made.

Friday’s session produced a nice intraday gain from a low of .0029 up to a new high of .0044, for a solid 52% upswing, and from the low we observed subsequent to our next most recent mention (.0009), it represented an overall increase of 389% in just under two week’s time.


Bottom-Watchlist

Both of the following stocks have recently fallen to new annual lows. We’re always on the lookout for potential bottom-bounce plays, so we’re going to want to place each of them on watch over the next few sessions.

Pain Therapeutics, Inc. PTIE – This stock underwent a massive gap-down and sell-off a couple weeks back following an FDA application denial for the extended release oxycodone capsules that the company has been licensed to develop since 2002.

We’re going to track it closely as it searches for its ultimate lows, which, if present indicators are any guide, could be forthcoming at any time now.

Cosi, Inc. COSI – While there is no gap to the upside on the COSI chart, we can see the same sort of major selloff that occurred a couple of weeks ago, and continuing up until Friday, when a new 52-week low was recorded.

As you can see on the snapshots, however, COSI is even more heavily oversold than the previously mentioned play. The volatility of its precipitous decline is what interests us most in tracking the stock for its eventual rebound.


Extended Watchlist:
GRNH, MYDX, HADV, HMPQ, JAMN, CRNT, TSRO,

Blue Horseshoe Stocks: OWCP’s Epic Run Persists & More

OWC Pharmaceutical Research Corp. OWCP

At this point, over a week since we first alerted on OWCP, we’re beginning to run out of superlatives to describe the uptrend that has now persisted over the span of an entire trading week. It’s increased by leaps and bounds each day, and yesterday produced one of the biggest intraday rips yet.

From its morning low of .035, the stock pushed its way to a new high of .073 for a solid double-bagger (+109%) on the day, and an absolutely massive rise of 1522% over our observed low from last Thursday.

Just as we stated in yesterday morning’s report, we want to keep our heads on a swivel concerning OWCP moving forward. When this monstrous breakout finally does end, opportunities for a subsequent dip-and-rip may present themselves, and at that point we’ll be ready to strike once again.


Ruby Tuesday, Inc. RT

We haven’t talked about Ruby Tuesday’s in our reports for nearly two years, but we see good cause to take a moment to revisit it today. Instances in which we see clear-cut short to moderate-term opportunities in both a stock and its associated options chain are rare indeed, but it appears we have just that with RT.

As you can see on the snapshot below, it just set a new 52-week low yesterday, but there was a notable recovery before market close wherein the stock recouped more than half of its daily losses. It makes RT a prime bottom-bounce candidate, and our other favorite indicators, the RSI and the MACD are both strongly suggesting that a more sustained rebound could be in the cards.



Additionally, we’re going to keep an eye on the RT 11/18 $2.50 Calls for a possible short to mid-term options trading opportunity if the recovery in RT plays out as we suspect it might.

______

Added Note: We also placed the DIS 11/11 $94-96 Calls on extended watch yesterday and the stock did begin to make the move up we were banking on there, so we’ll continue to track those closely as well.


Extended Watchlist:
AGTK, APYP, HNR, RGSE, PJET